Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Century Therapeutics' Depreciation and Depletion fell 509.55% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 493.46%. This contributed to the annual value of $13.3 million for FY2024, which is 199.33% up from last year.
  • As of Q3 2025, Century Therapeutics' Depreciation and Depletion stood at $3.1 million, which was down 509.55% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Depreciation and Depletion peaked at $3.6 million during Q4 2023, and registered a low of $1.2 million during Q1 2022.
  • In the last 4 years, Century Therapeutics' Depreciation and Depletion had a median value of $3.2 million in 2025 and averaged $3.0 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 15068.97% in 2023, then crashed by 753.9% in 2025.
  • Over the past 4 years, Century Therapeutics' Depreciation and Depletion (Quarter) stood at $2.8 million in 2022, then rose by 25.16% to $3.6 million in 2023, then fell by 6.59% to $3.3 million in 2024, then dropped by 5.7% to $3.1 million in 2025.
  • Its Depreciation and Depletion was $3.1 million in Q3 2025, compared to $3.2 million in Q2 2025 and $3.2 million in Q1 2025.